A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Goals of work Comparing antiemetic efficacy of different 5-HT(3)-receptor antagonists (5-HT(3)RAs) is difficult due to inter-study variability. Therefore, a meta-analysis was performed to comparatively evaluate dolasetron, granisetron, ondansetron and tropisetron for acute chemotherapy-induced nausea and vomiting (CINV).Patients and methods Comparisons between 5-HT(3)RAs were based on 44 randomized studies (including 12,343 patients) identified by MEDLINE, CANCERLIT or EMBASE searches and subcategorized by chemotherapy type (cisplatin- or non-cisplatin-based).Main results When all studies were combined, granisetron was equivalent to ondansetron (n = 27), and showed an advantage vs tropisetron (p = 0.018; n = 12). Ondansetron vs tropisetron (n = 11) and ondansetron vs dolasetron (n = 3) revealed equivalence in each comparison. An advantage for 3 mg granisetron vs 8 mg ondansetron was found in non-cisplatin-based studies (p = 0.015; n = 6). Overall equivalence was seen between ondansetron, 24 or 32 mg, and granisetron, 2 or 3 mg, for all studies (n = 13). There was a possible advantage for higher (24 or 32 mg) vs lower (8 mg) ondansetron dose regimens with cisplatin-based trials (n = 6). No differences were seen between 3 and 1 mg granisetron doses (n = 6).Conclusions Efficacy of 5-HT(3)RAs for preventing CINV following cisplatin- and non-cisplatin-based chemotherapy is comparable, with the exception of granisetron vs tropisetron. Some differences were noted in dosing subanalyses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, there are ample data demonstrating the efficacy of these agents in CINV and postoperative nausea and vomiting (PONV) in treating acute, delayed, and anticipatory nausea and vomiting.70, 71”
Citations
Cites
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205 · cited 1×
“Combined odds ratios were generated using Mantel-Haenszel pooling of contingency tables (fixed effect model as the standard approach) [68, 70].”
MethodMeta‐Analysis Of Controlled Clinical Trials
Whitehead, A. (2002) · doi:10.1002/0470854200 · Cited by 827
Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
Maeda, K., Chung, Y. S., Ogawa, Y., Kang, S., Ogawa, M., Sawada, T., & Sowa, M. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960301)77:5<934::aid-cncr20>3.0.co;2-3 · Cited by 639
Gralla, R., Lichinitser, M., Van der Vegt, S., Sleeboom, H., Mezger, J., Peschel, C., Tonini, G., Labianca, R., Macciocchi, A., & Aapro, M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg417 · Cited by 467
Eisenberg, P., Figueroa‐Vadillo, J., Zamora, R., Charu, V., Hajdenberg, J., Cartmell, A., Macciocchi, A., & Grunberg, S. (2003) · Cancer · doi:10.1002/cncr.11817 · Cited by 400
Aapro, M. S., Grunberg, S. M., Manikhas, G. M., Olivares, G., Suarez, T., Tjulandin, S. A., Bertoli, L. F., Yunus, F., Morrica, B., Lordick, F., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl137 · Cited by 338
Kaiser, R., Sezer, O., Papies, A., Bauer, S., Schelenz, C., Tremblay, P.-B., Possinger, K., Roots, I., & Brockmöller, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.064 · Cited by 251
Nonsteroidal antiinflammatory drugs and colorectal cancer
Muscat, J. E., Stellman, S. D., & Wynder, E. L. (1994) · Cancer · doi:10.1002/1097-0142(19941001)74:7<1945::aid-cncr2820740720>3.0.co;2-c · Cited by 198
Hesketh, P. J., Navari, R. M., Grote, T., Gralla, R. J., Hainsworth, J. D., Kris, M. G., Anthony, L. B., Khojasteh, A., Tapazoglou, E., Benedict, C. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2242 · Cited by 145
Perez, E. A., Hesketh, P. J., Sandbach, J. F., Reeves, J., Chawla, S., Markman, M. M., Hainsworth, J. D., Bushnell, W., & Friedman, C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.754 · Cited by 136
Research works printed but not linked: 6
- Huc P, Block S, Carlier D et al (1998) Oral granisetron versus oral ondansetron for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapies. Bull Cancer (Paris) 85:562–568
- Mabro M, Kerbrat P (1999) Etude comparative du granisetron per os et de l’ondansetron IV chez des patientes recevant une chimiotherapie pour un cancer du sein. Bull Cancer (Paris) 86:295–301
- Massidda B, Laconi S, Foddi M et al (1994) Prevention of non-cisplatin induced emesis: role of the antagonists of 5-HT3 receptors. Ann Oncol 5:204
- Mendarte L, Aguas CM, Martinez BE et al (2000) Meta-analysis of granisetron versus ondansetron: efficacy and safety in the prevention of acute emesis induced by high dose cisplatin containing schedules. Med Clin (Barcelona) 115:456–460
- Monde M, Grazie M, De Vita F et al (1994) Tropisetron vs granisetron nell’emesi acuta e ri-tardata indotta da cis-platino: dati preliminary. Tumori 80:150 (Abstr 428)
- Multinational Association for Supportive Care in Cancer (2005) Antiemetic guidelines from the Consensus Conference on Antiemetic Therapy. Perugia International Cancer Conference VII. Perugia, Italy; 29–31 March 2004. Support Care Cancer 13:77–79; 80–84; 85–96; 97–103; 104–108; 109–111; 112–116; 117–121; 122–128; 129–131
Cited by
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield, M. R., Chesney, M., Clark-Snow, R. A., Flaherty, A. M., Freundlich, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4614 · Cited by 1,059
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting
Navari, R. M., & Aapro, M. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1515442 · Cited by 477
Jordan, K., Gralla, R., Jahn, F., & Molassiotis, A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.073 · Cited by 192
Self-citationJordan, K., Sippel, C., & Schmoll, H.-J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1143 · Cited by 188
Self-citationVenkatesan, T., Levinthal, D. J., Tarbell, S. E., Jaradeh, S. S., Hasler, W. L., Issenman, R. M., Adams, K. A., Sarosiek, I., Stave, C. D., Sharaf, R. N., et al. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13604 · Cited by 137
Chemotherapy-Induced Nausea and Vomiting
Lohr, L. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e31816a0f07 · Cited by 144
Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management
Rapoport, B. L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00019 · Cited by 140
Chemotherapy-induced nausea and vomiting: optimizing prevention and management.
Rao, K. V., & Faso, A. (2012) · PubMed Central · Cited by 100
Comparative activity of antiemetic drugs
Jordan, K., Schmoll, H., & Aapro, M. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.08.003 · Cited by 95
Self-citationBotrel, T. E. A., Clark, O. A. C., Clark, L. G., Paladini, L. M., Faleiros, E., & Pegoretti, B. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-010-0908-8 · Cited by 85
on behalf of the Sancuso Study Group, Boccia, R. V., Gordan, L., Clark, G., Howell, J. D., & Grunberg, S. M. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-010-0990-y · Cited by 84
Serotonin receptor antagonists for highly emetogenic chemotherapy in adults
Billio, A., Morello, E., & Clarke, M. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006272.pub2 · Cited by 68
RetractedLevin, D. N., Dulberg, Z., Chan, A., Hare, G. M. T., Mazer, C. D., & Hong, A. P. (2017) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-017-0814-3 · Cited by 65
Likun, Z., Xiang, J., Ba, Y., Xin, D., & Tao, Z. L. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0198 · Cited by 63
A Review of Granisetron, 5-Hydroxytryptamine3 Receptor Antagonists, and Other Antiemetics
Hsu, E. S. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181ea7821 · Cited by 56
Ettinger, D. S., Armstrong, D. K., Barbour, S. Y., Berger, M. J., Bierman, P. J., Bradbury, B., Ellis, G. K., Kirkegaard, S., Kloth, D. D., Kris, M. G., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0047 · Cited by 57
Tricco, A. C., Blondal, E., Veroniki, A. A., Soobiah, C., Vafaei, A., Ivory, J. D., Strifler, L., Cardoso, R., Reynen, E., Nincic, V., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0761-9 · Cited by 49
Hu, Z., Cheng, Y., Zhang, H., Zhou, C., Han, B., Zhang, Y., Huang, C., Chang, J., Song, X., Liang, J., et al. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-2043-9 · Cited by 46
Ranganath, P., Einhorn, L. H., & Albany, C. (2015) · BioMed Research International · doi:10.1155/2015/943618 · Cited by 43
Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines
Tageja, N., & Groninger, H. (2015) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-132969 · Cited by 40
Rojas, C. J., & Slusher, B. S. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.09.005 · Cited by 32
Sikorskii, A. E., Given, C. W., You, M., Jeon, S., & Given, B. A. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.09.007 · Cited by 32
Antiemetic Use in Oncology: Updated Guideline Recommendations from ASCO
Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Somerfield, M. R., & Lyman, G. H. (2012) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2012.32.230 · Cited by 31
Jin, Y., Sun, W., Gu, D.-Z., Yang, J., Xu, Z., & Chen, J. (2012) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2012.01353.x · Cited by 30
Spartinou, A., Nyktari, V., & Papaioannou, A. A. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1396317 · Cited by 26
Jin, Y. J., Wu, X., Guan, Y., Gu, D., Shen, Y. L., Xu, Z., Wei, X., & Chen, J. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1280-z · Cited by 23
Evolving Treatment Paradigms for Chemotherapy-Induced Nausea and Vomiting
Wickham, R. (2012) · Cancer Control · doi:10.1177/107327481201902s02 · Cited by 23
Wickham, R. (2010) · PubMed · Cited by 22
Hsu, Y.-C., Chen, C., Tam, K.-W., & Hsu, C.-Y. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03157-2 · Cited by 18
Aridome, K., MORI, S.-I., Baba, K., Yanagi, M., Hamanoue, M., Miyazono, F., Tokuda, K., Imamura, H., Ogura, Y., Kaneko, K., et al. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.724 · Cited by 20
Belluomini, L., Avancini, A., Sposito, M., Pontolillo, L., Tregnago, D., Trestini, I., Insolda, J., Carbognin, L., Milella, M., Bria, E., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104444 · Cited by 25
Huang, J., Wang, X.-J., Ding, Y., Jin, Y.-N., ZHEN, L.-Z., Xu, N., Liu, W., DENG, Y.-C., Wu, S., & He, J. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.996 · Cited by 19
Du, Q., Zhai, Q., Zhu, B., Xu, X.-L., & Yu, B. (2016) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216652212 · Cited by 19
Chan, S. L., Jen, J., Burke, T. A., & Pellissier, J. M. (2014) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12170 · Cited by 18
Simino, G. P. R., Marra, L. P., Andrade, E. I. G., Acúrcio, F. D. A., Reis, I. A., de Araújo, V. E., & Cherchiglia, M. L. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1190271 · Cited by 17
Mahrous, M. A., El-Azab, G. A., & Tawfik, H. A. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04257-7 · Cited by 17
Carbamazepine for prevention of chemotherapy-induced nausea and vomiting: a pilot study
Santana, T. A., Cruz, F. M., Trufelli, D. C., Glasberg, J., & del Giglio, A. (2014) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2014.1323600 · Cited by 16
Kim, H. J., Shin, S. W., Song, E., Lee, N.-R., Kim, J. S., Ahn, J. S., Yun, H., Cho, Y.-H., Park, K. U., Kim, S.-Y., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0128 · Cited by 16
Controlling emesis: evolving challenges, novel strategies.
Nevidjon, B., & Chaudhary, R. T. (2010) · PubMed · Cited by 19
Clinical Update on Palonosetron in the Management of Chemotherapy-Induced Nausea and Vomiting
Celio, L., Denaro, A., Canova, S., Gevorgyan, A., & Bajetta, E. (2008) · Tumori Journal · doi:10.1177/030089160809400401 · Cited by 15
Vrabel, M. (2007) · Clinical journal of oncology nursing · doi:10.1188/07.cjon.809-813 · Cited by 15
Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials
Daimon, T. (2007) · Contemporary Clinical Trials · doi:10.1016/j.cct.2007.12.001 · Cited by 15
Chasen, M. R., & Rapoport, B. L. (2016) · Future Oncology · doi:10.2217/fon.16.11 · Cited by 14
PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics
Huddart, R., Altman, R. B., & Klein, T. E. (2019) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000369 · Cited by 19
Tsuji, D., Kim, Y.-I., Taku, K., Nakagaki, S., Ikematsu, Y., Tsubota, H., Maeda, M., Hashimoto, N., Kimura, M., & Daimon, T. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1185-x · Cited by 13
Aapro, M., Zhang, L., Yennurajalingam, S., LeBlanc, T. W., & Schwartzberg, L. S. (2019) · Future Oncology · doi:10.2217/fon-2018-0872 · Cited by 13
Santana, T. A., Trufelli, D. C., Matos, L. L., Cruz, F. M., & del Giglio, A. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2392-z · Cited by 14
Keat, C. H., & Ghani, N. A. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.12.7701 · Cited by 11
Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore
Lopes, G. D. L., Jr., Burke, T. A., Pellissier, J. M., Zhang, X.-H., Dedhiya, S. D., & Chan, A. (2012) · Value in Health Regional Issues · doi:10.1016/j.vhri.2012.03.002 · Cited by 11
Uchino, J., Hirano, R., Tashiro, N., Yoshida, Y., Ushijima, S., Matsumoto, T., Ohta, K., Nakatomi, K., Takayama, K., Fujita, M., et al. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.8.4187 · Cited by 12
Araz, M., Karaağaç, M., Korkmaz, L., Koral, L., İnci, F., Beypınar, İ., Uysal, M., & Artaç, M. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03831-4 · Cited by 10
Rapoport, B. L. (2017) · Cancer Management and Research · doi:10.2147/cmar.s97543 · Cited by 12
Zeitoun, A., & Nassif, J. G. (2011) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2011.01770.x · Cited by 7
Neue antiemetische Strategien – nicht nur in der Onkologie
Jordan, K., Müller, F., & Schmoll, H. (2009) · Der Internist · doi:10.1007/s00108-009-2411-1 · Cited by 11
Self-citationCelio, L., Agustoni, F., Ricchini, F., Dotti, K. F., Niger, M., & de Braud, F. (2013) · Future Oncology · doi:10.2217/fon.13.153 · Cited by 7
Celio, L., Agustoni, F., Testa, I., Dotti, K. F., & de Braud, F. (2012) · Tumori Journal · doi:10.1177/030089161209800301 · Cited by 6
Chemotherapy-Induced Nausea and Vomiting
Liso, E. D. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96194 · Cited by 8
New Insights into the Future of Pharmacoepidemiology and Drug Safety
Herdeiro, M. T., Roque, F., Figueiras, A., & Silva, T. M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.87642 · Cited by 9
Aleyasin, A., Hanafi, S., Saffarieh, E., Torkamandi, H., Alahyari, S., Sadeghi, F., & Javadi, M. (2012) · Europe PMC (PubMed Central) · Cited by 5
liu, Y., Xue, F., Liu, X., Qi, X., & Zhou, J. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/157061 · Cited by 5
Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron
Bajetta, E. (2009) · Cancer Management and Research · doi:10.2147/cmar.s4739 · Cited by 5
Cyclic vomiting syndrome: From pathophysiology to treatment
Jiménez‐Castillo, R. A., Frazier, R., Venkatesan, T., & Remes-Troche, J. M. (2024) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2024.06.001 · Cited by 4
Serotonin receptor antagonists for highly emetogenic chemotherapy in adults
Billio, A., Morello, E., & Clarke, M. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006272.pub3 · Cited by 4
RetractedIssenman, R. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821597-5.00005-8 · Cited by 4
Chemotherapy-Induced Nausea and Vomiting #285
Tageja, N., & Groninger, H. (2014) · Journal of Palliative Medicine · doi:10.1089/jpm.2014.9392 · Cited by 3
Lou, Y. (2011) · Faculty of Health; Institute of Health and Biomedical Innovation · Cited by 7
Essential Drugs in Supportive Care
Estfan, B. N. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.03.012 · Cited by 2
Pharmacology of serotonin antagonists
Nouriel, J. E., & Oliveira, G. D. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781316135853.008 · Cited by 2
The effects of agomelatine, fluoxetine, and sertraline on rat bladder contraction in vitro
Görmüş, Z. I. S. (2023) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.14744/dajpns.2023.00218 · Cited by 2
Gastrointestinale Nebenwirkungen und Ernährung bei Tumortherapie
Mayer, F., Kanz, L., & Zürcher, G. (2007) · Der Onkologe · doi:10.1007/s00761-007-1293-x · Cited by 2
Chang, T. Y. (2014) · Pediatric oncology · doi:10.1007/978-3-662-44317-0_10 · Cited by 7
A kemoterápia okozta hányás csillapítása
Tóth, J., & Szántó, J. (2008) · Magyar Onkológia · doi:10.1556/monkol.52.2008.4.9 · Cited by 2
Nausea and Vomiting in Cancer Patients: Topic Review
Ibrahim, N. A. R. (2014) · Journal of Palliative Care & Medicine · doi:10.4172/2165-7386.1000i203 · Cited by 2
Evaluation of the Medication Safety of Chemotherapy Drugs
Jabalpeikar, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96758 · Cited by 2
Pharmakologie der 5‐HT3‐Antagonisten. Historie und neue Entwicklungen
Rex, A., Bert, B., & Fink, H. (2007) · Pharmazie in unserer Zeit · doi:10.1002/pauz.200700230 · Cited by 2
Real hopes in antiemetic therapy
Kogoniya, L. M. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-194 · Cited by 1
Arfiani, R. F., Susilo, D. H., & Suprapti, B. (2017) · Folia Medica Indonesiana · doi:10.20473/fmi.v52i3.5450 · Cited by 1
Ravasio, R., & Rosti, G. (2015) · Global & Regional Health Technology Assessment · doi:10.5301/grhta.5000195 · Cited by 1
Chemotherapy-induced Nausea and Vomiting
Nevadunsky, N. S., & Matulonis, U. A. (2009) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2009.05.1.10 · Cited by 1
Kirkegaard, S., Kloth, D. D., Kris, M. G., Lim, D. W., Markiewicz, M. A., Michaud, L. B., Rugo, H. S., Diller, H., Sorscher, S. M., Stucky-Marshall, L., et al. (2010) · Cited by 1
Olver, I. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1225-1_24
Hashizume, J., Higuchi, N., Sato, K., Kodama, Y., Matsunaga, N., Sakamoto, T., Yamaguchi, K., Nakamura, T., Kitahara, T., & Sasaki, H. (2016) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00603
AntiemesisPractice Guidelines in Oncology TM
Ettinger, D. S., Armstrong, D. K., Barbour, S. Y., Berger, M., Bierman, P. J., Bradbury, B., Ellis, G. K., Kirkegaard, S., Kloth, D. D., Kris, M. G., et al. (2009)
First-Generation 5-HT3 Receptor Antagonists
Chen, R., Deng, K., & Raftopoulos, H. (2016) · Springer eBooks · doi:10.1007/978-3-319-27016-6_3
Dronca, R. S., & Loprinzi, C. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1398-5.10018-9
Novotná, V., Pohanková, D., Sirák, I., & Petera, J. (2020) · Onkologie · doi:10.36290/xon.2020.050
Jordan, K., Olver, I., & Aapro, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-90990-5_26
Self-citationAapro, M., Jordan, K., & Feye, P. (2013) · doi:10.1007/978-1-907673-58-0_5
Self-citationRavasio, R., & Rosti, G. (2015) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2015.331
Síndrome de vómitos cíclicos: de la fisiopatología al tratamiento
Jiménez‐Castillo, R. A., Frazier, R., Venkatesan, T., & Remes-Troche, J. M. (2024) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2024.06.001 · Cited by 1
Son, K., Shin, J. S., Lee, S. H., Lee, S., Jung, S., Kim, W., Jung, D., Kim, T., Im, S., Lee, K.-H., et al. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08718-6 · Cited by 1
Panuganti, V. K., Alluri, C. V., Ramalingayya, G. V., Mohammad, J., KSSVV, S., Dundigalla, M. R., & Madala, P. K. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04820-6
Metadata
- Authors
- Jordan, K., Hinke, A., Grothey, A., Voigt, W., Arnold, D., Wolf, H.-H., & Schmoll, H.-J.
- Affiliations
- Martin Luther University Halle-Wittenberg (DE)
- WiSP Wissenschaftlicher Service Pharma GmbH (Germany) (DE)
- Mayo Clinic (US)
- Corresponding author
- Jordan, K.
- Venue
- Supportive Care in Cancer
- Published
- 2007-01-05
- Volume
- 15
- Issue
- 9
- Pages
- 1023-1033
- ISSN
- 0941-4355 (ISSN-L)
- 1433-7339
- OpenAlex
- W2013631853
- Cited by
- 93
- References
- 71
- Citations by year
- 2025: 1 · 2024: 5 · 2023: 2 · 2022: 1 · 2021: 5 · 2020: 1 · 2019: 4 · 2018: 1 · 2017: 5 · 2016: 8 · 2015: 7 · 2014: 7 · 2013: 7 · 2012: 10
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Supportive Care in Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- 5-HT3 receptor antagonists, chemotherapy-induced nausea and vomiting, antiemetic efficacy, granisetron, ondansetron, tropisetron, dolasetron, cisplatin-based chemotherapy, drug dose comparison, drug efficacy comparison
- MeSH terms
- Tropisetron, Antiemetics, Antineoplastic Agents, Humans, Indoles, Quinolizines, Serotonin Antagonists, Vomiting, Treatment Outcome, Ondansetron, Granisetron, Serotonin 5-HT3 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.